ZIOPHARM Oncology (NASDAQ:ZIOP)

CAPS Rating: 2 out of 5

Results 1 - 7 of 7

Recs

0
Member Avatar pchop123 (78.31) Submitted: 4/12/2014 5:49:21 PM : Outperform Start Price: $3.65 ZIOP Score: -9.56

good pick now

Recs

0
Member Avatar MystereX (60.78) Submitted: 11/1/2013 1:39:54 PM : Outperform Start Price: $3.55 ZIOP Score: -11.07

Ad-RST-IL-12 UPDATE

Recs

0
Member Avatar SqwiiTrader (37.30) Submitted: 9/26/2013 5:35:43 AM : Outperform Start Price: $3.20 ZIOP Score: -4.77

monthly IHS

Recs

5
Member Avatar zzlangerhans (99.73) Submitted: 7/27/2013 8:57:52 PM : Underperform Start Price: $3.05 ZIOP Score: -0.14

If you follow biopharma stocks, you've no doubt been to biopharma websites. In that case, you've seen the ubiquitous stock photo on the company home page showing the smiling individual, often elderly, often outdoors, clearly enjoying life. The idea, I'm sure, is to get you into the right frame of mind before reading their press releases. Don't believe the hype? Might as well punch that smiling old person in the face.

Ziopharm isn't content to assault their visitors with one of these stock photos. Their homepage is a mosaic of dozens of pictures of smiling models who have absolutely no connection to their company. Drag your mouse over a picture ... and it lights up! Get a good look at these people who were never helped by Ziopharm's unapproved drugs which have never demonstrated any benefit in advanced clinical trials. Does it give you a warm and toasty feeling? Good. Now explore the website, and try not to be put off by the nauseating grey on black layout and ten point font.

Ziopharm has been exhumed from recent lows of 1.6 with new enthusiasm about recently inlicensed pipeline compound Ad-RTS IL-12. All is forgiven regarding the serial destruction of the original pipeline of darinaparsin, indibulin, and most recently palifosfamide. After all, Ziopharm is now going to cure melanoma. Forgive my skepticism. Intrexon has been all over the the biopharma sector of late with partnerships with such stellar outfits as Soligenix, Fibrocell, and Synthetic Biologics. Compared to those monkeys, Ziopharm looks like a movie star. I don't see Intrexon as anyone's knight in shining armor, unless you're just looking for a reason to keep the lights on and pay management salaries for another four or five years.

Recs

0
Member Avatar Ezquire65 (31.93) Submitted: 5/22/2012 2:57:23 PM : Outperform Start Price: $4.74 ZIOP Score: -58.78

A true speculative play with huge upside potential. With master investory RJ Kirk behind this security and from all accounts many promising developments. This could be the proverbial 5 bagger holy grail that FOOLS rarely see.

Recs

1
Member Avatar mavrant (< 20) Submitted: 6/2/2011 12:36:29 PM : Outperform Start Price: $6.74 ZIOP Score: -91.97

possible new technology

Recs

1
Member Avatar AGCAPS1 (44.11) Submitted: 1/26/2011 10:19:00 AM : Underperform Start Price: $5.98 ZIOP Score: +87.23

First review the released statements since 2009. Then read about what this company does. They research on eliminations of the existent cancer drugs side effects. This company works in drugs researching provided by Intrexon. If they become successful “many years away”, most likely the Intrexon will be the one profit from it. The stock is overpriced.

Results 1 - 7 of 7

Featured Broker Partners


Advertisement